547.74
price up icon2.40%   12.83
pre-market  Pre-mercato:  549.18   1.44   +0.26%
loading
Precedente Chiudi:
$534.91
Aprire:
$533.66
Volume 24 ore:
817.89K
Relative Volume:
0.64
Capitalizzazione di mercato:
$56.52B
Reddito:
$14.09B
Utile/perdita netta:
$4.50B
Rapporto P/E:
13.94
EPS:
39.28
Flusso di cassa netto:
$2.96B
1 W Prestazione:
+5.28%
1M Prestazione:
+11.60%
6M Prestazione:
-23.41%
1 anno Prestazione:
-47.57%
Intervallo 1D:
Value
$529.69
$551.50
Intervallo di 1 settimana:
Value
$514.79
$551.50
Portata 52W:
Value
$476.49
$1,211.20

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Nome
Regeneron Pharmaceuticals Inc
Name
Telefono
(914) 847-7000
Name
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Dipendente
15,158
Name
Cinguettio
@regeneron
Name
Prossima data di guadagno
2025-02-04
Name
Ultimi documenti SEC
Name
REGN's Discussions on Twitter

Confronta REGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-30 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-05-30 Downgrade Wells Fargo Overweight → Equal Weight
2025-05-14 Aggiornamento Citigroup Neutral → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-05 Aggiornamento Leerink Partners Market Perform → Outperform
2025-01-16 Downgrade UBS Buy → Neutral
2024-12-10 Ripresa BofA Securities Underperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Neutral
2024-09-24 Downgrade Leerink Partners Outperform → Market Perform
2024-03-12 Iniziato Bernstein Outperform
2024-01-12 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-03 Aggiornamento Raymond James Mkt Perform → Outperform
2023-08-21 Aggiornamento Canaccord Genuity Hold → Buy
2023-08-21 Reiterato Oppenheimer Perform
2023-06-28 Downgrade Canaccord Genuity Buy → Hold
2023-03-27 Aggiornamento SVB Securities Market Perform → Outperform
2023-03-24 Aggiornamento Jefferies Hold → Buy
2023-03-23 Aggiornamento Raymond James Underperform → Mkt Perform
2023-01-30 Aggiornamento Cowen Market Perform → Outperform
2023-01-20 Aggiornamento JP Morgan Neutral → Overweight
2022-10-26 Downgrade Raymond James Mkt Perform → Underperform
2022-10-17 Downgrade Evercore ISI Outperform → In-line
2022-09-09 Aggiornamento Jefferies Underperform → Hold
2022-09-09 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-07-25 Downgrade SVB Leerink Outperform → Mkt Perform
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-06 Iniziato Jefferies Underperform
2022-05-23 Iniziato SVB Leerink Outperform
2022-01-05 Downgrade BofA Securities Neutral → Underperform
2022-01-03 Aggiornamento Bernstein Mkt Perform → Outperform
2021-12-15 Downgrade Bernstein Outperform → Mkt Perform
2021-12-09 Ripresa Wells Fargo Overweight
2021-12-07 Ripresa Cowen Market Perform
2021-12-06 Iniziato Goldman Buy
2021-11-19 Ripresa BMO Capital Markets Outperform
2021-11-05 Downgrade The Benchmark Company Buy → Hold
2021-06-29 Iniziato H.C. Wainwright Buy
2021-01-25 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-01-13 Aggiornamento The Benchmark Company Hold → Buy
2021-01-08 Aggiornamento Citigroup Neutral → Buy
2020-10-05 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2020-08-20 Downgrade The Benchmark Company Buy → Hold
2020-07-09 Aggiornamento SunTrust Hold → Buy
2020-05-26 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-04-28 Downgrade Citigroup Buy → Neutral
2020-04-17 Aggiornamento The Benchmark Company Hold → Buy
2020-04-08 Iniziato The Benchmark Company Hold
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-02-26 Aggiornamento Canaccord Genuity Hold → Buy
2020-02-26 Downgrade Robert W. Baird Outperform → Neutral
2020-02-25 Aggiornamento Jefferies Hold → Buy
2020-02-11 Aggiornamento Argus Hold → Buy
2019-12-24 Iniziato Raymond James Mkt Perform
2019-12-16 Downgrade Evercore ISI Outperform → In-line
2019-12-13 Aggiornamento Credit Suisse Neutral → Outperform
2019-11-12 Iniziato SunTrust Hold
2019-11-07 Aggiornamento Citigroup Neutral → Buy
2019-10-17 Ripresa BofA/Merrill Neutral
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

pulisher
Jun 18, 2025

Regeneron Pharmaceuticals (REGN) Announces Key Decisions from 20 - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Regeneron Shareholders Approve Key Proposals at 2025 Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Grove Bank & Trust Has $514,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Exchange Traded Concepts LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Factory Mutual Insurance Co. Buys 8,200 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

Regeneron Steps Back, TTAM Aims To Reclaim 23andMe - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron (REGN) Exits 23andMe Bidding War - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

PKO Investment Management Joint Stock Co Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Schaper Benz & Wise Investment Counsel Inc. WI - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Breakthroughs in Uveitis Treatment Market Drive Global Demand - openPR.com

Jun 17, 2025
pulisher
Jun 17, 2025

Harbor Capital Advisors Inc. Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 17, 2025
pulisher
Jun 16, 2025

23andme founder-led group outbids Regeneron for company - BioWorld MedTech

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals says declined to submit new bid on 23andMe exceeding original $256 mln - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Fifth Third Bancorp Sells 952 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Anne Wojcicki overcomes Regeneron in 23andMe assets battle - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Anne Wojcicki’s Nonprofit Tops Bid for 23andMe Assets - Contract Pharma

Jun 16, 2025
pulisher
Jun 16, 2025

Patient Data Revolution: New Blockchain Platform Challenges Regeneron's $600M 23andMe Data Grab - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

BDF Gestion Has $2.82 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Dupixent demonstrated superiority over Xolair in chronic rhinosinusitis - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Warther Private Wealth LLC - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Mn Services Vermogensbeheer B.V. Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Silver Scott Health, Inc. Unveils Health Trust NFT to Empower Patient Data Control in Response to Regeneron's $600 Million 23andMe Bid - The Globe and Mail

Jun 16, 2025
pulisher
Jun 16, 2025

Sanofi, Regeneron Say Dupixent Outperforms Xolair in Phase 4 Respiratory Trial - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

RMR Wealth Builders Acquires Shares of 2,141 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Osprey Private Wealth LLC Makes New $2.24 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Pallas Capital Advisors LLC Invests $426,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Sanofi: positive data in chronic rhinosinusitis - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Smithbridge Asset Management Inc. DE Invests $3.41 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Leerink Partnrs Issues Negative Forecast for REGN Earnings - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by NorthCrest Asset Manangement LLC - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Sanofi, Regeneron Report Encouraging Results from Head-to-head Respiratory Study - MarketScreener

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron (REGN) and Sanofi's Dupixent Shows Superior Results in Key Phase 4 Trial | REGN Stock News - GuruFocus

Jun 15, 2025
pulisher
Jun 15, 2025

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe … - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Dupixent Outperforms Xolair in First-Ever Head-to-Head Trial for Nasal Polyps | REGN Stock News - Stock Titan

Jun 15, 2025
pulisher
Jun 15, 2025

Asio Capital LLC Has $2.53 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Greenwood Capital Associates LLC Invests $5.35 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis - Insider Monkey

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Wedmont Private Capital Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Handelsbanken Fonder AB - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Assenagon Asset Management S.A. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

New England Research & Management Inc. Invests $384,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Regeneron (REGN) Chosen as Backup Bidder in 23andMe Asset Sale | - GuruFocus

Jun 14, 2025
pulisher
Jun 14, 2025

Regeneron’s SWOT analysis: stock faces eylea challenges, pipeline potential - Investing.com

Jun 14, 2025

Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
McCourt Marion
EVP Commercial
Nov 01 '24
Option Exercise
381.40
1,000
381,400
13,931
McCourt Marion
EVP Commercial
Nov 01 '24
Sale
844.61
1,000
844,610
12,931
$329.77
price up icon 2.39%
$545.11
price up icon 0.49%
biotechnology ONC
$244.32
price down icon 0.34%
$108.26
price up icon 0.70%
$98.24
price up icon 0.64%
Capitalizzazione:     |  Volume (24 ore):